Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has achieved an objective response at 12 months of treatment with PD-1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (TKI) - SPICI

计划入组 372 人 · 首次发布于 2024 年 7 月 17 日

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

计划入组 1,769 人 · 首次发布于 2019 年 9 月 3 日

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

计划入组 246 人 · 首次发布于 2016 年 7 月 6 日

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Axl tyrosine kinase inhibitors (SuperGen)

EGFR tyrosine kinase inhibitors (breast cancer)

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL

EGFR-TKIs Pose Highest Cardiovascular Risk Among Tyrosine Kinase Inhibitors, Meta-Analysis Finds

Tyrosine Kinase Inhibitors and Gene Therapies Show Promise for Wet AMD Treatment